Company
Ipsen
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
6
6 still marketed
Novel approvals
5
Approvals since 2021
8
Originals and new uses
Phase 3 trials
84
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Bylvay new use OrphanDec 19, 2025
- Sohonos new use OrphanMar 13, 2025
- Iqirvo approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanJun 10, 2024
- Increlex new use OrphanMar 15, 2024
- Onivyde new use OrphanFeb 13, 2024
- Sohonos approved NovelPriority reviewOrphanAug 16, 2023
- Bylvay new use Priority reviewOrphanJun 13, 2023
- Bylvay approved NovelPriority reviewOrphanJul 20, 2021
- Somatuline Depot new use OrphanSep 15, 2017
- Onivyde approved Priority reviewOrphanOct 22, 2015
Drugs in development (7)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- CorabotaseIPN10200Phase 37 trials
Ipsen · Moderate to Severe Glabellar Lines, Spasticity, Moderate to Severe Upper Facial Lines
- IPN60340Phase 31 trial
Ipsen · Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia
- IPN01194Phase 21 trial
Ipsen · Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
- IPN01195Phase 21 trial
Ipsen · Advanced Solid Tumor
- IPN01203Phase 21 trial
Ipsen · Advanced Solid Tumor, Metastatic Solid Tumor
- IPN60300Phase 21 trial
Ipsen · Locally Advanced Solid Tumor, Metastatic Solid Tumor
- IPN60350Phase 21 trial
Ipsen · Neoplasms, Neoplasm Metastasis, Neoplastic Processes
Recruiting Phase 3 trials
Largest first.
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisPivotal-lookingRecruiting
IpsenIndustry
NCT07387549 · 350 participants (planned) · Start May 14, 2026 · Primary completion Apr 30, 2031
Drug: Elafibranor · For: Primary Sclerosing Cholangitis
Sites: Chandler, Arizona; Phoenix, Arizona; Coronado, California · 231 sites in all
- A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisPivotal-lookingRecruiting
IpsenIndustry
NCT06016842 · 276 participants (planned) · Start Aug 31, 2023 · Primary completion May 31, 2029
Drug: Elafibranor · For: Primary Biliary Cholangitis (PBC)
Sites: Tucson, Arizona; Little Rock, Arkansas; Coronado, California · 198 sites in all
- A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the EyebrowsPivotal-lookingRecruiting
IpsenIndustry
NCT07779252 · 160 participants (planned) · Start Aug 25, 2026 · Primary completion Apr 10, 2028
Drug: Corabotase; Placebo · For: Moderate to Severe Glabellar Lines
Sites: Guangzhou, China; Changsha, China; Nanjing, China · 9 sites in all
Marketed drugs (6)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.